Regulatory & Industry
| 6 min read
MCP and MHS promise to solve lab integration at last, but regulated environments demand more than connectivity before they can trust the results.
| 4 min read
The critical question they all should be asking is, “How can AI advance our drug development strategy?” rather than, “What’s our AI strategy?”
| 4 min read
Positive Alzheimer's trial data, workforce reductions, mRNA cancer therapy updates, and more led the news this week.
| 3 min read
Facing a tight financing market, the CRISPR biotech will wind down two off-the-shelf cell therapies as investor money shifts toward in vivo CAR T.
| 10 min read
Thirty years after women were formally brought into clinical research, inclusion has improved but important questions remain about how sex, pregnancy, and menopause affect drug safety and efficacy.
| 4 min read
Proteomic studies, billion dollar pharma deals, WHO initiatives, and more led the news this week.
| 3 min read
John Yu built Kairos Pharma on a simple bet: Cancer drugs don't fail, tumors just learn to outrun them.
| 1 min read
From AI agents to cell therapy to Alzheimer’s drug pipelines, this issue follows the same problem across three fields:what it takes to turn something that works once into something that works at scale.
| 4 min read
Pharma deals, regulatory updates, new treatments and more led the news this week.
| 4 min read
Antibody discovery is becoming less about finding the strongest binder and more about finding molecules that can survive the journey to the clinic.
| 4 min read
A win for autoimmune disease, a set back for Alzheimer’s disease, an FDA backing for a multi-cancer blood test, and more led the news this week.
